Pioneering The New Mobile Health Paradigm: A Conversation With AliveCor’s David Albert, MD

A new, mobile monitoring technology has entered the cardiovascular market, and companies that already own a piece of the landscape are paying close attention to its debut. Start-up AliveCor Inc. has launched a heart rhythm monitor that works with smartphones – one of the first of a new breed of mobile medical devices that could have a disruptive impact on health care as it is performed today.

As mobile health takes steps toward becoming an integral part of mainstream medical care, a number of interesting, new mobile-enabled technologies are making their way into the marketplace. (See Also see "Wireless Technology And The Rise Of “Anywhere” Monitoring" - Medtech Insight, 25 October, 2012., Also see "Mobile Health Promises To Uproot, Uplift Medical Devices" - Medtech Insight, 30 November, 2011., and Also see "Wireless and Mobile Monitoring: Bringing Health Care Home" - Medtech Insight, 1 March, 2011..) One of the most intriguing thus far comes from start-up AliveCor Inc., which recently launched its AliveCor Heart Monitor, designed to work with the iPhone 4 and 4S. (See Exhibit 1.) The device received clearance from the US Food and Drug Administration in November as a Class II medical device with an indication to record, display, store, and transfer single-channel ECG (electrocardiogram) rhythm strips. Its accuracy has been supported by several clinical studies, and the company believes the device – which some initially dismissed as a mere novelty – could ultimately become a disruptive medical technology. As a result, other medical device manufacturers – especially the established players in the cardiovascular space – are closely watching AliveCor’s progress.

David E

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By 

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

Beyond The Bladder: Incontinence Impacts Mental Health

 

In recognition of Mental Health Awareness month, Sarah Jenkins, executive director at the National Association for Continence, discussed the mental health issues that often come with incontinence.

More from North America

AI Rollout Aims To Accelerate FDA’s Product Review Process

 
• By 

The FDA plans to implement artificial intelligence in its scientific review process by 30 June, following a successful pilot. The agency hopes the tool will reduce nonproductive tasks for reviewers amid recent staff cuts. A Chief AI Officer will oversee the rollout and integration.

Access To Library Tools Being Restored At US FDA

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.

FDA Announces Classifications On 9 Device Types

 
• By 

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.